Author:
Psotka Mitchell A.,Abraham William T.,Fiuzat Mona,Filippatos Gerasimos,Lindenfeld JoAnn,Ahmad Tariq,Felker G. Michael,Jacob Richard,Kitzman Dalane W.,Leifer Eric S.,Lewis Eldrin F.,Mentz Robert J.,Nkulikiyinka Richard,Ni Wei,Schaber Daniel E.,Sharma Abhinav,Solomon Scott D.,Stockbridge Norman,Teerlink John R.,Unger Ellis F.,Whellan David J.,Wittes Janet,Anker Stefan D.,O’Connor Christopher M.
Subject
Cardiology and Cardiovascular Medicine
Reference47 articles.
1. Improving heart failure therapeutics development in the United States: the Heart Failure Collaboratory;O’Connor;J Am Coll Cardiol,2018
2. Dapagliflozin in patients with heart failure and reduced ejection fraction. Reply;McMurray;N Engl J Med,2020
3. Vericiguat in patients with heart failure and reduced ejection fraction;Armstrong;N Engl J Med,2020
4. Endpoints in heart failure drug development: history and future;Fiuzat;J Am Coll Cardiol HF,2020
5. Are surrogate markers adequate to assess cardiovascular disease drugs?;Temple;JAMA,1999
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献